Overview

This trial is active, not recruiting.

Condition metastatic breast cancer
Sponsor Latin American Cooperative Oncology Group
Collaborator Novartis
Start date June 2015
End date June 2016
Trial size 767 participants
Trial identifier NCT02662868, LACOG 0312

Summary

The purpose of this study is to describe demographics and socioeconomics characteristics associated to the diagnosis of metastatic breast cancer in Brazil.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective

Primary Outcomes

Measure
Description of sociodemographic and socioeconomics characteristics associated to diagnostic and treatment of metastatic breast cancer in Brazil
time frame: 8 months

Secondary Outcomes

Measure
Description of demographic characteristics of metastatic breast cancer patients
time frame: 8 months
The clinical and pathological characteristics of patients with metastatic breast cancer
time frame: 8 months
Prior treatment for breast cancer before metastatic disease
time frame: 8 months
The description of the clinical outcome of the patient diagnosed with metastatic breast cancer
time frame: 8 months
Type of treatment after the diagnosis of metastatic breast cancer
time frame: 8 months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Women > 18 years old - Patients diagnosed with de novo or recurrent metastatic breast cancer during the period of January to December 2012 - Any invasive breast cancer histology and subtype Exclusion Criteria: - Male breast cancer

Additional Information

Official title Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments
Description The primary aim of this study is to characterize patients and treatments of metastatic breast cancer in Brazil. Other specific aims are: - to describe patients demographics and socioeconomic characteristics - to describe the BC pathological characterization - to describe treatment (describe each treatment with dates start-end, cycles, dosing, sequence and line of treatment, reason for discontinuation) - to analyze patients outcome (time to progression, site of metastasis, progression free survival (PFS), overall survival (OS), skeletal related events (SRE))
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Latin American Cooperative Oncology Group.